Osteoarthritis remains one of the most significant causes of reduced performance and premature retirement in the equine athlete. | Adobe StockOsteoarthritis (OA) remains one of the most significant causes of reduced performance and premature retirement in the equine athlete. While long associated with the older horse, the underlying process chronic, low-grade inflammation that gradually compromises cartilage, synovial fluid, and the joint capsule frequently begins much earlier in life than clinical signs would suggest. By the time lameness, stiffness, or reduced performance becomes apparent, the joint has typically been adapting for some time.Osteoarthritis is progressive and, while manageable, currently not curable. That reality places considerable importance on early intervention. The risk factors are well established and largely unavoidable in working horses: the cumulative load of training and competition, conformational predispositions, work surfaces, and the demands of starting horses young in many disciplines. The clinical question is no longer whether to support joint health, but when.4CYTE Epiitalis Forte is an advanced daily oral supplement, scientifically proven to enhance joint health and function in horses, and suitable for long-term use. It is powered by Epiitalis, a globally patented plant seed oil extract that is the world-exclusive active ingredient in the 4CYTE range. Epiitalis is patented for its ability to help maintain healthy cartilage development. The unique fatty acid profile of the extract is understood to play a signaling role to chondrocytes (cells responsible for cartilage maintenance), supporting the cartilage matrix, helping maintain a normal inflammatory response, and supporting healthy cartilage and joint function.The evidence base is product-specific rather than ingredient-only, which is uncommon in the joint supplement category. Peer-reviewed work conducted at Colorado State University, including research involving Professor Wayne McIlwraith, examined Epiitalis in horses following joint injury. Over a 70-day period, horses receiving Epiitalis showed significant reductions in total radiographic scoresan indicator of OA progressioncompared with placebo, alongside a significant reduction in inflammation within the synovial fluid. Additional studies have been conducted at the University of Guelph, in Canada, and the University of Melbourne, in Australia.In clinical use 4CYTE Epiitalis Forte is suitable for long-term use and can be given from 6 months of age. It is suitable for use alongside other treatments a veterinarian might prescribe for joint health managementa practical consideration in cases where multimodal approaches are appropriate. The supplement is administered as a once-daily oral dose, is highly palatable, easily digestible, and readily absorbed, which supports the consistent daily administration that long-term joint support requires.From a practice perspective, the strongest case for prevention is straightforward. Joint function will most likely begin to decline well before clinical signs appear. The window in which intervention can support, rather than respond to, structural change is therefore narrower than it often seems at the point of presentation. With proactive measures incorporated into a horses daily management, many horses can continue to perform soundly into their late teens and beyondan outcome that aligns with both welfare considerations and the practical realities of performance-horse careers.4CYTE Epiitalis Forte is surgeon- and veterinarian-endorsed, backed by peer-reviewed and published studies, and represents an evidence-based addition to a comprehensive approach to equine joint health. As the conversation in performance-horse practice continues to shift from management of established disease toward earlier, structured support, the case for incorporating proven joint health interventions earlier in a horses working life becomes increasingly difficult to set aside.To learn more about 4CYTE Epiitalis Forte and the research behind Epiitalis, visit www.4cyte.global.